drugset / Trial / NCT00629967

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

NCT00629967

RandomizedParallel-groupOpen-labelTreatment

Summary

The purposes of this study are: 1. To evaluate whether treatment with peginterferon and ribavirin for 24 weeks is sufficient to achieve a sustained virological response (SVR) rate comparable to that observed with the standard treatment duration of 48 weeks, in hepatitis C virus genotype 1 (HCV-1) patients achieving a rapid virologic response (RVR; \<50 IU/mL HCV RNA at week 4) at 4 weeks. 2. To investigate the role of on-treatment virological responses among patients with 24 or 48 weeks treatment.

Timeline

Start
2005-04
Primary completion
2007-05
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Comparator Ribavirin Small molecule 1000 mg
Comparator Ribavirin Small molecule 1200 mg